An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Early Stage HER2+ Breast Cancer
Interventions: DRUG: Neratinib|DRUG: Loperamide|DRUG: Colestipol|DRUG: Budesonide
Sponsor: Puma Biotechnology, Inc.